Valve's SteamOS officially expands to third-party devices, with an upcoming handheld gaming PC set to ship with the Steam ...

Valve is changing the frequency and content of Deadlock updates going forward, and this is good for the long term health of ...

After two decades, the Federer/Nadal/Djokovic dynasty is ending. Are Jannik Sinner and Carlos Alcaraz the new ‘untouchables’?

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company’s ...

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of ...

Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage ...

( MENAFN - IANS) New Delhi, Jan 8 (IANS) Kala-azar or visceral leishmaniasis -- a deadly neglected tropical disease -- can be ...

Combining Adderall with other CNS stimulants, such as caffeine, can increase the risk of side effects, including elevated ...

Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension. Additionally, untreated moderate-to-severe OSA increases the ...

Investing.com -- Shares of Vir Biotechnology, Inc. (NASDAQ: VIR) surged 29% following the release of encouraging safety and efficacy data from ongoing dose escalation trials for its dual-masked T-cell ...